2025-06-13-Jefferies-吉利德科学（GILD）_今日邀请准备获批_对6_19_PDUFA_+推出动态的思考_9页_681kb
报告摘要
- Company: Gilead Sciences, Inc. (GILD) is a leader in anti-viral drugs for HIV/AIDS, Hepatitis, and oncology, with a growing pipeline.
- Rating: BUY with a price target of $130 (+16% upside from current $112.05) based on a DCF model and multiple of EPS.
- Product: Focus on Lenacapavir (Len) for PrEP and HIV treatment; upcoming PDUFA approval on June 19, 2025.
- Sales Projections: Consensus estimates for 2025 include $150M-200M in combined PrEP and treatment sales; potential of $160-200M for PrEP alone if high swap rates (e.g., 4-5% of 400k PrEP users), implying up to $5B peak market opportunity.
- Market Opportunity: Competition from Descovy, Truvada, and Apretude; Jefferies believes a strong market with high demand for switching, supported by surveys showing 70% awareness and ~90% willingness to swap from current treatments.
- Risks: Pipeline disappointments, competition, regulatory uncertainty, potential lower sales than consensus. Analysts certify no compensation directly tied to recommendations.
- Key Points: Analysts highlight visibility toward higher EPS ($10 vs. $8) and potential for $1.2B+ revenue from swap rates by 2026.
展开完整摘要
试读结束，高清完整版pdf/doc/ppt,请点下载
